Drug-resistant HER2-positive breast cancer: Molecular mechanisms and overcoming strategies
文献类型：期刊论文
| 作者 | Wu, Xiaofan; Yang, Hongjian; Yu, Xingfei; Qin, Jiang-Jiang |
| 刊名 | FRONTIERS IN PHARMACOLOGY
 |
| 出版日期 | 2022-09-23 |
| 卷号 | 13 |
| 关键词 | HER2 breast cancer targeted therapy drug resistance overcoming strategies |
| DOI | 10.3389/fphar.2022.1012552 |
| 通讯作者 | Yu, Xingfei(yuxf1177@zjcc.org.cn) ; Qin, Jiang-Jiang(jqin@ucas.ac.cn) |
| 英文摘要 | Breast cancer is one of the most common malignancies and the leading cause of cancer-related death in women. HER2 overexpression is a factor for poor prognosis in breast cancer, and anti-HER2 therapy improves survival in these patients. A dual-targeted combination of pertuzumab and trastuzumab, alongside cytotoxic chemotherapy, constitutes the primary treatment option for individuals with early-stage, HER2-positive breast cancer. Antibody-drug conjugate (ADC) and tyrosine kinase inhibitors (TKI) also increase the prognosis for patients with metastatic breast cancer. However, resistance to targeted therapy eventually occurs. Therefore, it is critical to investigate how HER2-positive breast cancer is resistant to targeted therapy and to develop novel drugs or strategies to overcome the resistance simultaneously. This review aims to provide a comprehensive discussion of the HER2-targeted agents currently in clinical practice, the molecular mechanisms of resistance to these drugs, and the potential strategies for overcoming resistance. |
| WOS关键词 | EPIDERMAL-GROWTH-FACTOR ; FACTOR RECEPTOR ; DOUBLE-BLIND ; TRASTUZUMAB RESISTANCE ; PI3K PATHWAY ; ANTIBODY ; HER2 ; PLACEBO ; GENE ; PERTUZUMAB |
| 资助项目 | Qiantang Cross Fundation ; Wu Jieping Medical Foundation[320.6750.2021-10-30] ; Project of Zhejiang Medical and Health Science and Technology Program[2020KY491] |
| WOS研究方向 | Pharmacology & Pharmacy |
| 语种 | 英语 |
| 出版者 | FRONTIERS MEDIA SA |
| WOS记录号 | WOS:000869974800001 |
| 资助机构 | Qiantang Cross Fundation ; Wu Jieping Medical Foundation ; Project of Zhejiang Medical and Health Science and Technology Program |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/129478]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 通讯作者 | Yu, Xingfei; Qin, Jiang-Jiang |
| 作者单位 | Univ Chinese Acad Sci, Zhejiang Canc Hosp, Inst Basic Med & Canc IBMC, Chinese Acad Sci,Canc Hosp, Hangzhou, Peoples R China |
| 推荐引用方式 GB/T 7714 | Wu, Xiaofan,Yang, Hongjian,Yu, Xingfei,et al. Drug-resistant HER2-positive breast cancer: Molecular mechanisms and overcoming strategies[J]. FRONTIERS IN PHARMACOLOGY,2022,13. |
| APA | Wu, Xiaofan,Yang, Hongjian,Yu, Xingfei,&Qin, Jiang-Jiang.(2022).Drug-resistant HER2-positive breast cancer: Molecular mechanisms and overcoming strategies.FRONTIERS IN PHARMACOLOGY,13. |
| MLA | Wu, Xiaofan,et al."Drug-resistant HER2-positive breast cancer: Molecular mechanisms and overcoming strategies".FRONTIERS IN PHARMACOLOGY 13(2022). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。